A Republican bill with 1 Republican cosponsor · See the cosponsor
Last activity — Referred to the House Committee on Energy and Commerce.
In committee
Introduced and handed to a committee in the chamber it started in.
The committee holds it, and most bills are never heard from again. A hearing or a committee vote would be news; silence is the usual outcome, and it kills the bill without anyone voting against it.
Its path through Congress
- Introduced
- In Committee
What this bill would do
This bill, known as the "Advancing Botanical Drug Development Act of 2026," aims to amend the Federal Food, Drug, and Cosmetic Act. It proposes providing a specific period of market exclusivity for botanical drugs. The legislation seeks to address the unique scientific and manufacturing challenges associated with plant-derived raw materials. By creating these incentives, the bill intends to encourage private investment in the research and development of these therapies. The goal is to increase treatment options for chronic and age-related diseases.
Yes· 3 of 8
- Scored +4
Would people over 65 be better off under this?
The bill specifically targets chronic and age-related diseases which frequently affect seniors.
- Scored +4
Would retired people be better off under this?
The focus on age-related diseases provides potential health benefits for retirees.
- Scored +4
Does this make health care easier to get in general?
By incentivizing botanical drug development, the bill seeks to increase treatment options for patients with chronic diseases.
The opposite
No question was scored the opposite.
Who it would affect, and how
Potential Positive Impacts for People
-
Increased Treatment Options: Expanding incentives may increase multi-target treatment options for patients suffering from multi-pathway, chronic, and age-related diseases (Section 2, Finding 8).
-
Market Exclusivity for Botanical Drugs: A botanical drug approved under specific criteria would be entitled to a 12-year period where certain other applications cannot become effective (Section 3).
-
Encouraging Innovation: The bill suggests that providing tailored periods of regulatory exclusivity can encourage innovation and facilitate long-term investment in research and development (Section 2, Finding 7).
Potential Negative Impacts for People
- Increased Development Burdens: The development of botanical drugs involves unique scientific and manufacturing challenges, such as the need for extensive sourcing controls and consistency testing, which may increase costs (Section 2, Finding 5).
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Tap or hover a score for the reason it gave.
- Demographic And Interest Groups
- Would retired people be better off under this? — The focus on age-related diseases provides potential health benefits for retirees. Would people over 65 be better off under this? — The bill specifically targets chronic and age-related diseases which frequently affect seniors. Would business owners be better off under this? — The bill provides incentives for pharmaceutical companies and researchers to invest in botanical drugs. Would people with disabilities be better off under this? — Increased treatment options may benefit individuals living with chronic diseases and disabilities.
- Healthcare
- Does this make health care easier to get in general? — By incentivizing botanical drug development, the bill seeks to increase treatment options for patients with chronic diseases.
- Economy And Finance
- Is this likely to grow the economy? — The bill aims to promote economic growth by encouraging private investment in botanical drug research and development.
- Education And Technology
- Does this make patent and copyright rules fairer? — The bill provides specific market exclusivity to protect intellectual property for botanical drugs.
- Governance And Ideology
- Does this give the federal government more power? — The bill amends the Federal Food, Drug, and Cosmetic Act, utilizing federal regulatory authority.
- 8/27/2026
- Referred to the House Committee on Energy and Commerce.
- 1 Cosponsor added.
- Introduced in House
Derrick Van OrdenRepublican · Wisconsin